ImmunityBio (IBRX) FCF Margin (2014 - 2026)
ImmunityBio (IBRX) reported FCF Margin of 174.58% for Q1 2026, up 34552.0% year-over-year from N/an in Q1 2025, and up 6.23% quarter-over-quarter from 186.19% in Q4 2025.
ImmunityBio (IBRX) FCF Margin (2014 - 2026) Analysis & Trends
ImmunityBio (IBRX) has 13 years of FCF Margin data on file, last reported at 174.58% in Q1 2026.
- FCF Margin for Q1 2026 came in at 174.58%, up 34552.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 212.84% (up 96869.0% YoY), and the FY2025 annual result was 272.56%, up 238078.0% from the prior year.
- FCF Margin improved to 174.58% in Q1 2026 per IBRX's latest filing, from 186.19% in the prior quarter.
- Over five years, FCF Margin peaked at 174.58% in Q1 2026 and troughed at 542792.86% in Q1 2022.
- A 5-year average of 101746.61% and a median of 28706.39% in 2023 frame the typical range for FCF Margin.
- The sharpest annual moves came in 2022 and 2023: FCF Margin plunged 49622020 bps in 2022, then soared 51408647 bps in 2023.
- A 5-year view of FCF Margin shows it stood at 124590.41% in 2022, then climbed by 29 bps to 88651.8% in 2023, then soared by 99 bps to 1064.18% in 2024, then jumped by 83 bps to 186.19% in 2025, then grew by 6 bps to 174.58% in 2026.
- Business Quant data shows IBRX's FCF Margin at 174.58% in Q1 2026, 186.19% in Q4 2025, and 219.88% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -3.98% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 43.35% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | ImmunityBio | 7.55 Bn | 7.17 Bn | 43.97 Mn | -174.58% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -174.58% |
| Dec 31, 2025 | -186.19% |
| Sep 30, 2025 | -219.88% |
| Jun 30, 2025 | -306.90% |
| Mar 31, 2025 | -520.10% |
| Dec 31, 2024 | -1,064.18% |
| Sep 30, 2024 | -1,663.20% |
| Jun 30, 2024 | -9,653.39% |
| Mar 31, 2024 | -270,607.50% |
| Dec 31, 2023 | -88,651.80% |
| Sep 30, 2023 | -119,560.98% |
| Jun 30, 2023 | -177,395.12% |
| Mar 31, 2023 | -28,706.39% |
| Dec 31, 2022 | -124,590.41% |
| Sep 30, 2022 | -67,470.34% |
| Jun 30, 2022 | -296,128.57% |
| Mar 31, 2022 | -542,792.86% |
| Dec 31, 2021 | -15,418.72% |
| Sep 30, 2021 | -132,619.70% |
| Jun 30, 2021 | -21,733.04% |